Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Ten new research projects will tackle the root cause of life-changing autoimmune conditions
In autoimmune conditions, our immune systems attack healthy cells in the body
Ten new autoimmunity research projects will receive nearly £1 million from the partnership of the Lorna and Yuti Chernajovsky Biomedical Research Foundation and Connect Immune Research, a coalition of immune-related medical research charities.
The ten new 12-month pilot projects will explore how to target the links between multiple autoimmune conditions to increase our understanding and generate new treatments.
The ultimate aim of this initiative is to deliver significant new investment to confront the UK’s high prevalence of autoimmunity and develop new treatments for multiple autoimmune conditions, faster.
In all autoimmune conditions, our immune systems attack healthy cells in the body, causing symptoms that have the potential to severely limit people’s lives. They affect an estimated four million people in the UK – equivalent to more than six per cent of the population – but are currently incurable. Examples include type 1 diabetes, coeliac disease, multiple sclerosis (MS), psoriasis, rheumatoid arthritis and alopecia.
Although these conditions affect different parts of the body, we know that they are somehow linked, and that better understanding this link will pave the way to improved treatments for all autoimmune conditions.
As Maxine Pancaldi, an autoimmune patient representative notes, “It is incredibly encouraging to see this collaboration gather speed. Having the combined involvement and input of all parties enriches the goals and outcomes and brings additional direction for researchers. It truly gives hope to those of us living with autoimmune conditions that a concentration of minds, resources and findings will unlock the mysteries of the immune system.”
The studies funded by this initiative will take a number of approaches to increase our understanding of autoimmunity and how to treat it including:
This first round of pilot grants aims to quickly develop proof-of-principle for potential new treatments for multiple autoimmune conditions by examining similarities between the different diseases.
On completion, the most promising projects will be invited to apply for follow-on funding to take their work forward.
Professor Yuti Chernajovsky, Co-founder and Trustee of the Lorna and Yuti Chernajovsky Biomedical Research Foundation, said:
“The Chernajovsky Foundation is delighted to be funding these innovative translational research projects with our Connect Immune Research partners, which we hope will improve the lives of people living with autoimmune conditions. We look forward to seeing the projects develop as part of a new collaborative approach to research on autoimmunity.”
Rachel Connor, Director of Research Partnerships at the type 1 diabetes charity JDRF, said:
“These awards are evidence that the UK research community is just as determined as the Connect Immune Research partnership to think about autoimmunity in a new way. This funding partnership with the Chernajovsky Foundation has provided the opportunity for 10 teams to come together to tackle these complex life-changing diseases in new ways, and we are so excited to see where these pilot projects can lead.”
Dr Neha Issar-Brown, Director of Research and Health Intelligence at Versus Arthritis, said:
“We are determined to make arthritis preventable, treatable and curable. We know that our partners in this pioneering initiative are equally keen to understand and exploit the shared underlying immunological mechanisms for several other chronic, autoimmune conditions that severely limit people’s lives. Combining the heft, the resources and the expertise in a collaborative manner such as this is a sure way of ensuring research makes a bigger difference to people’s lives, at pace and we are delighted to be part of this forward-thinking endeavour.”
Nick Moberly, Chief Executive of the MS Society, said:
“We’re thrilled by the wide range of research projects receiving funding. They will help us gain a better understanding of autoimmune diseases with the ultimate aim of finding new treatments. MS is relentless, painful and disabling. Around a third of people living with an autoimmune condition have more than one, and they say they want us to do all we can to further research. The collaboration between the Connect Immune Research group and the Lorna and Yuti Chernajovsky Biomedical Research Foundation brings together researchers from across autoimmune conditions to uncover the common threads in their work. We hope this will lead to new treatments, faster.”
Dr Doug Brown, Chief Executive of the British Society for Immunology, said:
“Immunology is a vital branch of medical science in which the UK leads the world with new discoveries. Connect Immune Research has joined forces with the Lorna and Yuti Chernajovsky Biomedical Research Foundation to fund these innovative projects that prioritise a collaborative, integrated approach to autoimmune research. By building on the UK’s existing strength in autoimmune research, we aim to bring together the best brains in immunology to study different autoimmune diseases together, driving forward our understanding of the underlying biological mechanisms and developing new treatments, which will ultimately transform the lives of people living with these conditions.”
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.